Deciphering the clinical significance of longitudinal antiphospholipid antibody titers

• Published in: Autoimmunity reviews Vol. 23; no. 3; p. 103510
• Main Authors: Chighizola, Cecilia B., Willis, Rohan, Maioli, Gabriella, Sciascia, Savino, Andreoli, Laura, Amengual, Olga, Radin, Massimo, Gerosa, Maria, Atsumi, Tatsuya, de Jesus, Guilherme, Trespidi, Laura, Branch, D. Ware, Caporali, Roberto, Andrade, Danieli, Roubey, Robert, Petri, Michelle, Bertolaccini, Maria Laura
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2024
• Subjects: Allergy and Immunology; Antibodies, Antiphospholipid - blood; Antibodies, Antiphospholipid - immunology; Antibody titers; Antiphospholipid antibodies; Antiphospholipid Syndrome - blood; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - immunology; beta 2-Glycoprotein I - immunology; Clinical Relevance; Follow-up; Humans; Longitudinal; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - immunology; Seroconversion; Thrombosis; Thrombosis - blood; Thrombosis - etiology; Thrombosis - immunology; Antibody titers; Longitudinal; Antiphospholipid antibodies; Seroconversion; Thrombosis; Follow-up
• ISSN: 1568-9972; 1568-9972; 1873-0183
• DOI: 10.1016/j.autrev.2023.103510

In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the classification approach to aPL-positive subjects, the value of longitudinal monitoring of those titers in the follow-up is still debated, being well studied only in systemic lupus erythematosus (SLE). The literature suggests that the rate of aPL positivity decreases during follow-up in primary APS, estimating that seroconversion occurs in between 8.9 and 59% of patients over time. Negativisation of aPL occurs more frequently in asymptomatic aPL carriers than in patients with full-blown APS as well as in subjects with single aPL positivity or low aPL antibody titers. In patients with SLE, aPL typically behave fluctuating from positive to negative and back again in the course of follow-up. The few studies assessing the longitudinal course of aPL positivity with no associated systemic connective tissue disease reported a progressive decrement of aPL titers over time, in particular of antibodies against β2 glycoprotein I (antiβ2GPI) and cardiolipin (aCL) of IgG isotype. After a thrombotic event, aPL titers tend to decrease, as emerged from cohorts of both primary and secondary APS. Hydroxychloroquine has been identified as the most effective pharmacological agent to reduce aPL titers, with multiple studies demonstrating a parallel reduction in thrombosis rate. This review addresses available evidence on the significance of aPL titer fluctuation from clinical, therapeutic and pathogenic perspectives. •aPL seroconversion occurs in 8.9–59% of patients over time.•aPL negativisation occurs more in carriers, subjects with single positivity or low titers.•In patients with SLE, aPL keeps fluctuating from positive to negative.•After a thrombotic event, aPL titers tend to decrease.•Hydroxychloroquine is the most effective pharmacological agent to reduce aPL titers.